SinoMab BioScience Limited

Informe acción SEHK:3681

Capitalización de mercado: HK$1.4b

SinoMab BioScience Resultados de beneficios anteriores

Pasado controles de criterios 0/6

SinoMab BioScience's earnings have been declining at an average annual rate of -1.1%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 64.6% per year.

Información clave

-1.1%

Tasa de crecimiento de los beneficios

2.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 11.0%
Tasa de crecimiento de los ingresos-64.6%
Rentabilidad financiera-72.1%
Margen neto-9,961.9%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

Mar 04
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

Jan 28
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

Jan 01
Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

Nov 30
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

Desglose de ingresos y gastos

Cómo gana y gasta dinero SinoMab BioScience. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SEHK:3681 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 242-20082124
31 Mar 243-22190130
31 Dec 234-24398135
30 Sep 235-25998150
30 Jun 235-27499165
31 Mar 235-27991173
31 Dec 224-28483180
30 Sep 2219-301108186
30 Jun 2234-318134191
31 Mar 2230-303134195
31 Dec 2127-288133199
30 Sep 2120-22294172
30 Jun 2113-15655146
31 Mar 2113-13963124
31 Dec 2013-12372103
30 Sep 206-21786166
30 Jun 200-311100229
31 Mar 200-29481222
31 Dec 190-27662214
31 Dec 181-84947

Ingresos de calidad: 3681 is currently unprofitable.

Margen de beneficios creciente: 3681 is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 3681 is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.

Acelerando crecimiento: Unable to compare 3681's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 3681 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


Rentabilidad financiera

Alta ROE: 3681 has a negative Return on Equity (-72.09%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado